Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 83 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lexiscan Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Contrast- Enhanced Whole-Heart Coronary MRA at 3.0T (Tesla)

NCT02092428
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Image Quality, Diagnostic Accuracy
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 2 Interventional

A Single Center Study to Establish the Imaging Protocol of 99mTc-EC-DG in Evaluating the Presence and Severity of Coronary Artery Disease (CAD)

NCT01778218
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose
Radiation
Lead sponsor
Cell>Point LLC
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2013 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 4 Interventional Results available

Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction

NCT02597543
View directory record Official record
Conditions
Heart Transplant, Acute Graft Rejection, Chronic Graft Rejection
Interventions
Regadenoson, Gadolinium, Cardiac MRI
Drug · Procedure
Lead sponsor
Paul Kim
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 21, 2026, 3:47 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Whole-Heart Myocardial Blood Flow Quantification Using MRI

NCT03064295
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Microvascular Disease
Interventions
Myocardial Perfusion Cardiac MRI., Contrast, Pharmacologic Stress Agent
Device · Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 2 Interventional Results available

Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI

NCT01655043
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
Regadenoson, gadofoveset trisodium
Drug
Lead sponsor
Northwestern University
Other
Eligibility
19 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 1 Interventional Results available

Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease

NCT01085201
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Lexiscan
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
10 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2014 · Synced Oct 21, 2026, 3:47 PM EDT
Not listed Not applicable Interventional

Less Invasive Detection and Treatment of Very Early Coronary Artery Disease in Patients With Diabetes Mellitus

NCT00797186
View directory record Official record
Conditions
Type 2 Diabetes, Microvascular Dysfunction
Interventions
Intensive risk factor management
Other
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 1 Interventional Results available

Regadenoson R-T Perfusion Imaging Trial

NCT00837369
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Perfusion Abnormalities
Interventions
Regadenoson
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
30 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Rochester, Minnesota • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 21, 2026, 3:47 PM EDT
Terminated No phase listed Observational

The Evaluation of the Roles of New Cardiac Imaging in Patients With Chest Pain

NCT03800862
View directory record Official record
Conditions
Cardiology, Radiology, Stenoses
Interventions
CT-FFR and CTP
Device
Lead sponsor
Lancaster General Hospital
Other
Eligibility
45 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Early Phase 1 Interventional

Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System

NCT04521569
View directory record Official record
Conditions
Lung Transplant
Interventions
Regadenoson, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 21, 2026, 3:47 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Stress Induced Right Ventricular Uptake on Lexiscan Stress MPI

NCT01697995
View directory record Official record
Conditions
Increased Right Ventricular Radiotracer Uptake
Interventions
Not listed
Lead sponsor
Aiden Abidov
Other
Eligibility
18 Years to 89 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 4 Interventional Results available

Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)

NCT01019486
View directory record Official record
Conditions
Coronary Artery Disease, Type 1 Diabetes Mellitus
Interventions
Regadenoson myocardial perfusion imaging, Regadenoson MRI myocardial blood flow
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
25 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 21, 2026, 3:47 PM EDT
Not listed No phase listed Observational

Impact of Coronary Artery Stenting on Quantitative Myocardial Blood Flow and Health Status

NCT04475094
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Rubidium-82, Seattle Angina Questionnaire-7, Rose Dyspnea Scale
Drug · Behavioral
Lead sponsor
Cardiovascular Imaging Technologies
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 21, 2026, 3:47 PM EDT
Active, not recruiting No phase listed Observational

Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics

NCT01719016
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Cardiac PET, Coronary catheterization
Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 100 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 21, 2026, 3:47 PM EDT
Not listed Phase 4 Interventional

Diagnostic Study of Rapid Regadenoson Stress Cardiovascular Magnetic Resonance (CMR) to Detect Coronary Artery Disease

NCT01446094
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
regadenoson
Drug
Lead sponsor
Dipan Shah
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Oct 21, 2026, 3:47 PM EDT
Terminated Not applicable Interventional Results available

Simultaneous Assessment of FFR and SPECT

NCT02749045
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
SPECT imaging
Radiation
Lead sponsor
Prem Soman
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Not applicable Interventional

Reducing Radioisotope Dose: the Half-Dose CZT Study

NCT01518777
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Half-dose isotope for NuclearStressTest
Other
Lead sponsor
S.M.Chang, MD
Other
Eligibility
18 Years to 90 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 21, 2026, 3:47 PM EDT
Not listed No phase listed Observational

Evaluation of Myocardial Ischemia Using Standard Single Photon Emission Computed Tomography (SPECT) With Regadenoson and Simultaneous Cardiac Echocardiography

NCT01150578
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
No intervention
Drug
Lead sponsor
Aiden Abidov
Other
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF

NCT02589977
View directory record Official record
Conditions
Heart Failure, Diastolic, Diastolic Heart Failure, Hypertension
Interventions
regadenoson
Drug
Lead sponsor
Marvin W. Kronenberg, M.D.
Other
Eligibility
50 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 4 Interventional Results available

Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson

NCT01779869
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Regadenoson
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 4 Interventional Results available

A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease

NCT00862641
View directory record Official record
Conditions
Asthma, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive
Interventions
Regadenoson, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
1,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
48
States / cities
Montgomery, Alabama • Anaheim, California • Encinitas, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 3 Interventional Results available

Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

NCT00826280
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
regadenoson, overencapsulated caffeine, technetium, placebo
Drug · Radiation
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • La Mesa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 21, 2026, 3:47 PM EDT
Completed Phase 2 Interventional Results available

Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients

NCT01710254
View directory record Official record
Conditions
Atrial Fibrillation, Coronary Artery Disease
Interventions
Regadenoson MRI, Gadobenate dimeglumine
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 21, 2026, 3:47 PM EDT
Terminated No phase listed Observational

Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome

NCT03449888
View directory record Official record
Conditions
Veterans Referred to the St. Louis VAMC Stress Tes
Interventions
Regadenoson myocardial perfusion imaging stress test, Arm exercise electrocardiographic stress test, Treadmill electrocardiographic stress test, Coronary artery calcium score and cardiac computed tomographic angiography
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 100 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 21, 2026, 3:47 PM EDT